COMMUNIQUÉS West-GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/09/2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the [...]
Spyre Therapeutics Announces Grants of Inducement Awards
04/09/2026
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that [...]
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the [...]
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
04/09/2026
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21 st Annual Healthcare [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of [...]
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
04/09/2026
LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS
04/09/2026
BOCA RATON, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery [...]
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
04/09/2026
Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary [...]
Bright Minds Biosciences to Present at Upcoming Conferences
04/09/2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
04/09/2026
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE [...]
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
04/09/2026
TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating [...]
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
04/09/2026
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced [...]
Déclaration d’actions et de droits de vote - Statut au 31 août 2026
04/09/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 31 août 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social [...]

Pages